Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1811 results
October 2015
-
Story Discovery
Stopping Alzheimer's disease before it starts
Novartis collaborates with the Banner Alzheimer’s Institute to test treatments for preventing Alzheimer’s disease.
-
Media Release
Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases
Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and… -
Featured News
Industry and academia collaborating to innovate for patients
We are partnering with the Friedrich Miescher Institute on more than 50 research projects to improve and extend people’s lives.
-
Media Release
Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 years
Late-breaking data at EADV show that 8 out of 10 of psoriasis patients (83%) achieved 75% skin clearance (PASI 75) with CosentyxTM after three years[1] 6 out of 10 patients (64%) had… -
Media Release
Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
NEDA-4 - no evidence of disease activity based on four parameters - relapses, MRI lesions, brain shrinkage and disability progression - is a comprehensive measure of MS disease control 31.2%… -
Story Patient Perspectives
Debunking the myths about multiple sclerosis
We surveyed 7,000 people in seven countries to find out what they know about multiple sclerosis (MS). Our survey identified several surprising misconceptions.
-
Media Release
Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
AcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps maintain integrity of incision while facilitating smooth IOL delivery Follows earlier FDA approval… -
Media Release
FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept
Etanercept is an anti-TNF medicine used to treat a range of immunological diseases including rheumatoid arthritis and psoriasis. Sandoz is seeking approval for all indications included in the… -
Story Discovery
Novartis cancer researchers advance precision medicine
Learn how NIBR uses next generation sequencing to transform clinical trials and diagnostics in oncology.
September 2015
-
Media Release
Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
In the FUTURE 1 study, secukinumab showed rapid and significant efficacy in active psoriatic arthritis (PsA) patients, including improvement of skin and joint disease and reduction in progression of… -
Story Patient Perspectives
Heart failure: coping with one of the world’s biggest killers
Patients are learning to live with a chronic disease that will affect one in 5 people over age 40.
-
Media Release
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated…